Results 201 to 210 of about 379,942 (267)

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

<i>In vitro</i> assessment of foot-and-mouth disease vaccine immunogenicity: advances, challenges, and ethical considerations. [PDF]

Front Vet Sci
Othusitse L, Kabelo TI, Nkwe KA, Seoke L, Fana EM, Lebani K.   +5 more
europepmc   +1 more source

Discovery of 2H-Pyrrolo[3,4‑<i>c</i>]pyridin-3-one Derivatives as Type-III c‑MET Inhibitors Enabled by Free-Energy Perturbation Calculations. [PDF]

ACS Med Chem Lett
Therrien E, Feng S, Amberg-Johnson K, Shaikh N, Patil P, Majumdar S, Abraham N, Eiler D, Kutter S, Albanese SK, Haldar S, Kroeck KG, Atsriku C, Gerasyuto AI, Levinson AM.   +14 more
europepmc   +1 more source

Comment on Deeb et al.: interpretation of breath cannabinoids and implications for impairment. [PDF]

J Anal Toxicol
Olson A.
europepmc   +1 more source

Normalizing Covalent Potency for Electrophilicity with Ligand Reactivity Efficiency. [PDF]

J Med Chem
Horning BD, Kingston C, Simon GM, Patricelli MP, Weinstein DS, Cook BN.   +5 more
europepmc   +1 more source

Structural determinants of ligand response specificity in the mast cell activating GPCR, MRGPRX2. [PDF]

J Biol Chem
Adeosun AAR, Agosto MA, Lichtarge O, Wensel TG.   +3 more
europepmc   +1 more source

Discovery of Potent 1,3-Cyclobutane-Containing Dual A_2A/A_2B Receptor Antagonists with Low Projected Human Dose for the Treatment of Cancer. [PDF]

ACS Med Chem Lett
Brill ZG, Christian AH, Rico L, Schneider SE, Phillips EM, Winston MS, Krishnamurthy H, Hennessy ET, Mansoor UF, Xiao D, Su J, Liu P, Plummer C, Palmieri A, Vela Ramirez J, Hill A, Dewey W, Tatosian D, Rindgen D, Ogunbodede O, Smotrov N, Piesvaux J, Ciaccio P, Fan P, Afshar R, Daublain P, Presland J, Otte KM, Ali A, Cumming J, Ranganath S, DeMong D.   +31 more
europepmc   +1 more source